Healionics, a developer of synthetic biomaterial-based medical devices, today announced 12-month clinical results in the ongoing human trial of its STARgraft arteriovenous (AV) graft.
STARgraft is a new AV graft technology designed to provide kidney failure patients with a safer and more reliable way to access the bloodstream for hemodialysis treatment. Its design is aimed at resisting the most common causes of failure in on-market AV grafts: flow blockage and infection.
After refinement of the device over a series of clinical trials, STARgraft is showing remarkable promise in addressing these issues and reducing the need for interventions to maintain function. The cohort of twelve patients implanted with the current version of STARgraft has maintained 100% Primary Unassisted Patency (PUP) through 12 months post-implant, meaning zero interventions were required to maintain sufficient blood flow for dialysis therapy. The STARgraft devices have also maintained 0% infection rate.